Literature DB >> 29070650

Interleukin-12 from CD103+ Batf3-Dependent Dendritic Cells Required for NK-Cell Suppression of Metastasis.

Deepak Mittal1, Dipti Vijayan2, Eva M Putz2, Amelia R Aguilera2, Kate A Markey3,4, Jasmin Straube5, Stephen Kazakoff5, Stephen L Nutt6, Kazuyoshi Takeda7, Geoffrey R Hill3,4, Nicola Waddell5, Mark J Smyth1.   

Abstract

Several host factors may affect the spread of cancer to distant organs; however, the intrinsic role of dendritic cells (DC) in controlling metastasis is poorly described. Here, we show in several tumor models that although the growth of primary tumors in Batf3-deficient mice, which lack cross-presenting DCs, was not different from primary tumors in wild-type (WT) control mice, Batf3-deficient mice had increased experimental and spontaneous metastasis and poorer survival. The increased metastasis was independent of CD4+ and CD8+ T lymphocytes, but required NK cells and IFNγ. Chimeric mice in which Batf3-dependent DCs uniformly lacked the capacity to produce IL12 had metastatic burdens similar to the Batf3-deficient mice, suggesting that Batf3+ DCs were the only cell type whose IL12 production was critical for controlling metastasis. We found that IL12-YFP reporter mice, whose lungs were injected with B16F10 melanoma, had increased numbers of IL12-expressing CD103+ DCs with enhanced CD86 expression. Bone-marrow-derived DCs from WT, but not Batf3-deficient, mice activated NK cells to produce IFNγ in an IL12-dependent manner and therapeutic injection of recombinant mouse IL12 decreased metastasis in both WT and Batf3-deficient mice. Analysis of TCGA datasets revealed an association between high expression of BATF3 and IRF8 and improved survival of breast cancer patients; BATF3 expression also significantly correlated with NK-cell receptor genes, IL12, and IFNG Collectively, our findings show that IL12 from CD103+ DCs is critical for NK cell-mediated control of tumor metastasis. Cancer Immunol Res; 5(12); 1098-108. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29070650     DOI: 10.1158/2326-6066.CIR-17-0341

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  45 in total

1.  Exosome-Containing Preparations From Postirradiated Mouse Melanoma Cells Delay Melanoma Growth In Vivo by a Natural Killer Cell-Dependent Mechanism.

Authors:  Kishore Kumar Jella; Tahseen H Nasti; Zhentian Li; David H Lawson; Jeffrey M Switchenko; Rafi Ahmed; William S Dynan; Mohammad K Khan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-06-17       Impact factor: 7.038

2.  IL12 Abrogates Calcineurin-Dependent Immune Evasion during Leukemia Progression.

Authors:  Jennifer L Rabe; Lori Gardner; Rae Hunter; Jairo A Fonseca; Jodi Dougan; Christy M Gearheart; Michael S Leibowitz; Cathy Lee-Miller; Dmitry Baturin; Susan P Fosmire; Susan E Zelasko; Courtney L Jones; Jill E Slansky; Manali Rupji; Bhakti Dwivedi; Curtis J Henry; Christopher C Porter
Journal:  Cancer Res       Date:  2019-05-29       Impact factor: 12.701

3.  RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer.

Authors:  Elizabeth Ahern; Heidi Harjunpää; Jake S O'Donnell; Stacey Allen; William C Dougall; Michele W L Teng; Mark J Smyth
Journal:  Oncoimmunology       Date:  2018-02-14       Impact factor: 8.110

4.  Lung dendritic cells migrate to the spleen to prime long-lived TCF1hi memory CD8+ T cell precursors after influenza infection.

Authors:  Meagan M Jenkins; Holly Bachus; Davide Botta; Michael D Schultz; Alexander F Rosenberg; Beatriz León; André Ballesteros-Tato
Journal:  Sci Immunol       Date:  2021-09-10

Review 5.  NK Cells and ILC1s in Cancer Biology.

Authors:  Anna Sliz; Wayne M Yokoyama
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 6.  Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers.

Authors:  Alicia Cristina Peña-Romero; Esteban Orenes-Piñero
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

7.  Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression.

Authors:  Maureen L Drakes; Patrick J Stiff
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function.

Authors:  Deepak Mittal; Ailin Lepletier; William C Dougall; Mark J Smyth; Jason Madore; Amelia Roman Aguilera; Kimberley Stannard; Stephen J Blake; Vicki L J Whitehall; Cheng Liu; Mark L Bettington; Kazuyoshi Takeda; Georgina V Long; Richard A Scolyer; Ruth Lan; Nathan Siemers; Alan Korman; Michele W L Teng; Robert J Johnston
Journal:  Cancer Immunol Res       Date:  2019-03-20       Impact factor: 11.151

Review 9.  Immune crosstalk in cancer progression and metastatic spread: a complex conversation.

Authors:  Hannah Garner; Karin E de Visser
Journal:  Nat Rev Immunol       Date:  2020-02-05       Impact factor: 53.106

Review 10.  Recent Progress in Dendritic Cell-Based Cancer Immunotherapy.

Authors:  Kazuhiko Matsuo; Osamu Yoshie; Kosuke Kitahata; Momo Kamei; Yuta Hara; Takashi Nakayama
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.